US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 17:27:13 Source:sportViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Philippines blames China for loss of giant clams in disputed shoal and urges environmental inquiry
You may also like
- Rangers are undefeated at .500 to keep World Series champs from a losing record with Bochy
- Domestic passenger flights resume operation in Sanya
- Domestic passenger flights resume operation in Sanya
- Malaysia installs new king
- Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
- Mainland's adjustment to Straits flight route serves aviation safety
- New productive forces key to growth, Xi says
- China's digital economy hits 45 trln yuan: report
- Yvette Fielding says her Most Haunted co